Memantin Ratiopharm (Memantine Hydrochloride)

Memantine Hydrochloride is used in the management of neurodegenerative disorders, particularly Alzheimer’s disease, by targeting glutamatergic excitotoxicity.

• Alzheimer’s disease (moderate to severe): Improves cognition, functional abilities and behavioral symptoms in patients with moderate to severe disease.
• Alzheimer’s disease (mild to moderate, adjunct therapy): May be added to cholinesterase inhibitors to enhance overall symptom control.
• Behavioral symptoms in Alzheimer’s disease: Can help reduce agitation, aggression and other neuropsychiatric manifestations.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA‑type glutamate receptor. By binding to the receptor-associated ion channel with moderate affinity, it blocks excessive calcium influx caused by overstimulation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission essential for learning and memory.

Common Side Effects

• Dizziness: Transient sensation of light‑headedness, especially when standing quickly.
• Headache: Mild to moderate intensity, often resolving without intervention.
• Constipation: Decreased bowel movements that may improve with dietary fiber.
• Fatigue: Generalized tiredness that can affect daily activities.
• Confusion: Temporary disorientation, more frequent in the initial treatment period.

Serious or Rare Side Effects

• Seizures: New‑onset convulsive episodes requiring immediate medical attention.
• Severe allergic reactions: Rash, swelling, or difficulty breathing indicating possible anaphylaxis.
• Stevens‑Johnson syndrome: Rare skin blistering and mucosal involvement.
• Hepatic dysfunction: Elevated liver enzymes or jaundice.
• Suicidal thoughts: Emergence of depressive symptoms or suicidal ideation.

Memantine should be used with careful clinical monitoring.

• Renal impairment: Adjust dose in patients with reduced kidney function.
• Hepatic impairment: Monitor liver enzymes and consider dose modification.
• History of seizures: Use cautiously and observe for increased seizure activity.
• Concurrent NMDA antagonists: Avoid combining with other agents that block NMDA receptors.
• Pregnancy and breastfeeding: Safety not established; weigh potential benefits against risks.
• Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several medicines.

Major Interactions (Avoid)

• Amantadine: Combined use can increase central nervous system adverse effects.
• Other NMDA antagonists (e.g., ketamine): Additive neurotoxicity risk.
• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): May lower memantine plasma concentrations.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: May diminish therapeutic benefit.
• Diuretics: Potential for increased hypotension.
• Antihypertensive drugs: Monitor blood pressure for additive lowering effect.